Effects of Cholestasis on Whole Blood Concentration of Tacrolimus, an Immunosuppressant, in Living-Related Liver Transplant Recipients

DOI: 10.4236/ijcm.2013.410078   PDF   HTML     2,812 Downloads   4,002 Views   Citations


Background: To explore the effects of cholestasis on whole blood concentration of tacrolimus (TAC), an immunosup-pressant, we investigated the relationship among blood TAC concentration, bile flow, and TAC metabolites in bile, as well as the relationship between total bilirubin (T-Bil), an index of cholestasis, and blood TAC concentration, in liver transplant recipients. Methods: Data were collected retrospectively from 16 male and 19 female patients (mean age: 38 years; range: 12 -59 years) who had undergone a living-related liver transplantation at Kyoto Prefectural University of Medicine from 2004 through 2008. Analysis of TAC, demethyl-TAC, and hydroxy-TAC in bile was performed by LC-MS/MS. Results: There was no correlation between the ratio of TAC metabolite to TAC in bile (M/P) of demethyl-TAC and post operation days (POD), whereas a weak linear correlation was demonstrated between M/P of hydroxy-TAC and POD (r = 0.345). Moreover, linear correlations were not observed between M/P and the TAC trough level normalized dose (TLTAC/dose), and between TLTAC/dose and POD. A negative linear correlation was demonstrated between bile flow and T-Bil in blood (r = 0.495). Furthermore, a positive linear correlation was observed between TLTAC/dose and T-Bil (r = 0.598), whereas there was no correlation between bile flow and TLTAC/dose. Conclusions: Improvement of hepatic function and the increase of TAC clearance after postoperative day 7 did not significantly contribute to hepatic TAC metabolism, bile excretion, and TLTAC/dose. Postoperative biliary stricture from liver transplantation with/without biliary drainage caused inter-and intra-patient variability in TLTAC/dose after liver transplantation, which could be assessed by T-Bil. T-Bil in blood might be a predictive biomarker for determining the degree of bile duct stricture and TAC dose in liver transplantation patients. Along with an appropriate dosing regimen, therapeutic drug monitoring including T-Bil would be beneficial and enable individual adjustment of TAC dose in liver transplantation patients.

Share and Cite:

S. Kobuchi, K. Fukushima, Y. Maeda, T. Kokuhu, H. Ushigome, N. Yoshimura, N. Sugioka and K. Takada, "Effects of Cholestasis on Whole Blood Concentration of Tacrolimus, an Immunosuppressant, in Living-Related Liver Transplant Recipients," International Journal of Clinical Medicine, Vol. 4 No. 10, 2013, pp. 432-439. doi: 10.4236/ijcm.2013.410078.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] T. Kino, H. Hatanaka, M. Hashimoto, M. Nishiyama, T. Goto, M. Okuhara, M. Kohsaka, H. Aoki and H. Imanaka, “FK-506, a Novel Immunosuppressant Isolated from a Streptomyces. I. Fermentation, Isolation, and Physico-Chemical and Biological Characteristics,” The Journal of Antibiotics (Tokyo), Vol. 40, No. 9, 1987, pp. 1249-1255.
[2] T. Kino, H. Hatanaka, S. Miyata, N. Inamura, M. Nishiyama, T. Yajima, T. Goto, M. Okuhara, M. Kohsaka, H. Aoki, et al., “FK-506, a Novel Immunosuppressant Isolated from a Streptomyces. II. Immunosuppressive Effect of FK-506 in Vitro,” The Journal of Antibiotics (Tokyo), Vol. 40, No. 9, 1987, pp. 1256-1265.
[3] G. L. Plosker and R. H. Foster, “Tacrolimus: A Further Update of Its Pharmacology and Therapeutic Use in the Management of Organ Transplantation,” Drugs, Vol. 59, No. 2, 2000, pp. 323-389.
[4] E. M. Haddad, V. C. McAlister, E. Renouf, R. Malthaner, M. S. Kjaer and L. L. Gluud, “Cyclosporin versus Tacrolimus for Liver Transplanted Patients,” Cochrane Database System Review, Vol. 4, 2006, CD005161.
[5] C. E. Staatz and S. E. Tett, “Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation,” Clinical Pharmacokinetics, Vol. 43, No. 10, 2004, pp. 623-653.
[6] M. Naesens, D. R. Kuypers and M. Sarwal, “Calcineurin Inhibitor Nephrotoxicity,” Clinical Journal of the American Society of Nephrology, Vol. 4, No. 2, 2009, pp. 481-508. http://dx.doi.org/10.2215/CJN.04800908
[7] Tacrolimus (Prograf®), “Drug Information,” Astellas Pharma Inc., Tokyo, 2013.
[8] R. P. Kershner and W. E. Fitzsimmons, “Relationship of FK506 Whole Blood Concentrations and Efficacy and Toxicity after Liver and Kidney Transplantation,” Transplantation, Vol. 62, No. 7, 1996, pp. 920-926.
[9] P. McMaster, D. F. Mirza, T. Ismail, G. Vennarecci, P. Patapis and A. D. Mayer, “Therapeutic Drug Monitoring of Tacrolimus in Clinical Transplantation,” Therapeutic Drug Monitoring, Vol. 17, No. 6, 1995, pp. 602-605.
[10] G. W. Boswell, I. Bekersky, J. Fay, J. Wingard, J. Antin, D. Weisdorf, R. Maher, W. Fitzsimmons and R. Nash, “Tacrolimus Pharmacokinetics in BMT Patients,” Bone Marrow Transplant, Vol. 21, No. 1, 1998, pp. 23-28.
[11] W. J. Jusko, W. Piekoszewski, G. B. Klintmalm, M. S. Shaefer, M. F. Hebert, A. A. Piergies, C. C. Lee, P. Schechter and Q. A. Mekki, “Pharmacokinetics of Tacrolimus in Liver Transplant Patients,” Clinical Pharmacology & Therapeutics, Vol. 57, 1995, pp. 281-290.
[12] R. J. Stratta, R. P. Wood, A. N. Langnas, R. R. Hollins, K. J. Bruder, J. P. Donovan, D. A. Burnett, R. P. Lieberman, G. B. Lund, T. J. Pillen, et al., “Diagnosis and Treatment of Biliary Tract Complications after Orthotopic Liver Transplantation,” Surgery, Vol. 106, 1989, pp. 675-683.
[13] J. W. Ostroff, “Post-Transplant Biliary Problems,” Gastrointestinal Endoscopy Clinics of North America, Vol. 11, 2001, pp. 163-183.
[14] D. M. Minich, R. Havinga, F. Stellaard, R. J. Vonk, F. Kuipers and H. J. Verkade, “Intestinal Absorption and Postabsorptive Metabolism of Linoleic Acid in Rats with Short-Term Bile Duct Ligation,” American Journal of Physiology-Gastrointestinal and Liver Physiology, Vol. 279, No. 6, 2000, pp. G1242-G1248.
[15] R. J. Sokol, M. Devereaux, R. Khandwala and K. O’Brien, “Evidence for Involvement of Oxygen Free Radicals in Bile Acid Toxicity to Isolated Rat Hepatocytes,” Hepatology, Vol. 17, No. 5, 1993, pp. 869-881.
[16] G. Poli, “Pathogenesis of Liver Fibrosis: Role of Oxidative Stress,” Molecular Aspects of Medicine, Vol. 21, No. 3, 2000, pp. 49-98.
[17] G. Tahan, H. Akin, F. Aydogan, S. S. Ramadan, O. Yapicier, O. Tarcin, H. Uzun, V. Tahan and K. Zengin, “Melatonin Ameliorates Liver Fibrosis Induced by Bile-Duct Ligation in Rats,” Canadian Journal of Surgery, Vol. 53, 2010, pp. 313-318.
[18] S. Eguchi, M. Takatsuki, A. Soyama, M. Hidaka, I. Muraoka and T. Kanematsu, “Use of Stepwise versus Straightforward Clamping of Biliary Drainage Tubes after Living-Donor Liver Transplantation: A Prospective, Randomized Trial,” Journal of Hepato-Biliary-Pancreatic Surgery, Vol. 19, No. 4, 2012, pp. 379-381.
[19] M. L. Shiffman, R. L. Carithers Jr., M. P. Posner and E. W. Moore, “Recovery of Bile Secretion Following Orthotopic Liver Transplantation,” Journal of Hepatology, Vol. 12, No. 3, 1991, pp. 351-361.
[20] R. Venkataramanan, A. Jain, V. S. Warty, K. Abu-Elmagd, M. Alessiani, J. Lever, A. Krajak, J. Flowers, S. Mehta, S. Zuckerman, et al., “Pharmacokinetics of FK 506 in Transplant Patients,” Transplant Proceedings, Vol. 23, No. 6, 1991, pp. 2736-2740.
[21] M. Fukudo, I. Yano, S. Masuda, M. Goto, M. Uesugi, T. Katsura, Y. Ogura, F. Oike, Y. Takada, H. Egawa, S. Uemoto and K. Inui, “Population Pharmacokinetic and Pharmacogenomic Analysis of Tacrolimus in Pediatric Living-Donor Liver Transplant Recipients,” Clinical Pharmacology & Therapeutics, Vol. 80, 2006, pp. 331-345. http://dx.doi.org/10.1016/j.clpt.2006.06.008
[22] R. A. Koster, E. C. Dijkers and D. R. Uges, “Robust, High-Throughput LC-MS/MS Method for Therapeutic Drug Monitoring of Cyclosporine, Tacrolimus, Everolimus, and Sirolimus in Whole Blood,” Therapeutic Drug Monitoring, Vol. 31, No. 1, 2009, pp. 116-125.
[23] U. Christians, F. Braun, N. Kosian, M. Schmidt, H. M. Schiebel, L. Ernst, C. Kruse, M. Winkler, I. Holze, A. Linck, et al., “High Performance Liquid Chromatography/ Mass Spectrometry of FK 506 and Its Metabolites in Blood, Bile, and Urine of Liver Grafted Patients,” Transplant Proceedings, Vol. 23, 1991, pp. 2741-2744.
[24] M. Antignac, J. S. Hulot, E. Boleslawski, L. Hannoun, Y. Touitou, R. Farinotti, P. Lechat and S. Urien, “Population Pharmacokinetics of Tacrolimus in Full Liver Transplant Patients: Modelling of the Post-Operative Clearance,” European Journal of Clinical Pharmacology, Vol. 61, No. 5-6, 2005, pp. 409-416.
[25] S. Kobuchi, K. Fukushima, Y. Maeda, T. Kokuhu, H. Ushigome, N. Yoshimura, N. Sugioka and K. Takada, “Effects of Bile Duct Stricture on the Pharmacokinetics of the Immunosuppressant Tacrolimus in Rats,” Interactive Medicinal Chemistry, in press.

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.